Environ Health Perspect by Scinicariello, Franco et al.
Sequencing of the human genome has brought
new emphasis and increased interest in
gene–environment interactions and is becom-
ing relevant in defining public health policies.
For many years, people’s susceptibility to xeno-
biotics have been known to differ significantly.
Now, several techniques are available to iden-
tify and characterize the genetic correlates of
interindividual variability. The goal of environ-
mental genomics is to help investigators under-
stand how genetic variability influences
individual responses to environmental factors
on the basis of the assumption that high-risk
genotypes accumulate more damage and there-
fore are at greater risk of developing exposure-
related diseases. Thus, genomics information
may lead to development of predictive bio-
markers that identify potentially sensitive pop-
ulations and earlier prediction of adverse
outcomes, ultimately resulting in better inter-
vention strategies (Kelada et al. 2003).
Public Health and Perchlorate
The advent and use of new, highly sensitive
detection techniques have identified contami-
nation of groundwater by perchlorate in many
parts of the United States, primarily in associa-
tion with industries involved in rocket, explo-
sives, and fireworks manufacturing and
propellant handling. Concentrations measured
in most public water supplies are < 50 µg/L;
however, levels as high as several hundred
microliters per liter have been reported in some
drinking water wells in certain communities
(Motzer 2001). The recent detection of per-
chlorate in vegetable and dairy food products
(Kirk et al. 2003; Smith et al. 2001) indicates
that contamination by perchlorate is more
widespread than previously thought.
Perchlorate is the dissociated anion of per-
chlorate salts such as potassium perchlorate,
sodium perchlorate, and ammonium perchlo-
rate and is extremely water soluble and envi-
ronmentally stable. Therefore, the perchlorate
ion is identical whether derived from potas-
sium, sodium, or ammonium salts. Potassium
perchlorate was used primarily as a pharmaceu-
tical agent to treat hyperthyroidism. It is now
used mainly in flares and automobile airbags,
although it is still used for diagnostic purposes
and for treatment of hyperthyroidism. Sodium
perchlorate is used in the manufacture of slurry
explosives. Ammonium perchlorate is widely
used as a component of propellants for rockets,
missiles, and fireworks (Soldin et al. 2001).
Perchlorate was first detected in high con-
centrations by monitoring wells in California
during the early 1990s. When initially
detected in California, the Region 9 Office of
the U.S. Environmental Protection Agency
developed a provisional reference dose for
perchlorate of 0.0001 mg/kg/day in 1992.
The reference dose later was revised to
0.0005 mg/kg/day in 1995. These values
were based on a dated acute exposure study
that showed that single doses of potassium
perchlorate caused release of iodide from thy-
roids of patients with Graves disease, an
autoimmune condition that results in hyper-
thyroidism (Stanbury and Wyngaarden
1952). In 2005 the reference dose was
changed again to 0.0007 mg/kg/day.
Mode of Action of Perchlorate
in Humans
Perchlorate is a competitive inhibitor of the
sodium iodide symporter (NIS), the thyroid
cell–surface protein responsible for transport-
ing iodide from the plasma into the thyroid.
Therefore, it prevents further synthesis of the
thyroid hormone (TH). It has no effect on the
iodination process itself; rather, it displaces
iodide by competitive uptake at the NIS.
Perchlorate is concentrated by the thyroid tis-
sue in a manner similar to iodide, but it is not
significantly metabolized either in the gland or
peripherally (Wolff 1998). Eskandari et al.
(1997) disputed the notion that perchlorate is
translocated via NIS into the cell and that per-
chlorate acts on NIS as a blocker, not as a sub-
strate. Therefore, it is possible that perchlorate
may cross the thyrocyte membrane by diffu-
sion. In rats and humans, perchlorate appears
to be eliminated rapidly, primarily in urine
(> 90%), virtually unchanged (Anbar et al.
1959; Eichler and Hackenthal 1962).
Several other inorganic anions such as
thiocyanate and nitrate that are present in
dietary and environmental sources have goitro-
genic effects (Greer et al. 1966). Similar to per-
chlorate, they both competitively inhibit
iodide uptake at NIS. Several studies have been
conducted to determine the relative effects of
perchlorate, thiocyanate, and nitrate on
radioactive iodine uptake (RAIU) inhibition.
Studies in rats showed that perchlorate was
approximately 10 times more potent than
thiocyanate and about 300 times more potent
than nitrate in inhibiting RAIU in the thyroid.
Furthermore, thiocyanate was slightly more
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potent than iodide (Wyngaarden et al. 1953).
Tonacchera et al. (2004) demonstrated, in
Chinese hamster ovary (CHO) cell lines stably
transfected with the human NIS gene, that the
relative potency of perchlorate on RAIU inhi-
bition was 15, 30, and 240 times that of thio-
cyanate, iodide, and nitrate, respectively. The
inhibiting effects when the cell lines where
exposed to a mixture of perchlorate, thio-
cyanate, and nitrate were simply additive.
Thyroid Hormone Synthesis
Thyroid hormone plays a key role in the
growth and differentiation of many organs. It is
especially important for development of the
central nervous system during the prenatal and
postnatal periods (reviewed by Zoeller et al.
2002). A severe shortage of TH for several
weeks after birth results in serious mental and
motor handicaps. During pregnancy the
mother provides substantial amounts of TH to
the fetus (Vulsma et al. 1989), so the delay in
cerebral development caused by congenital
hypothyroidism (CH) results mainly from post-
natal TH deficiency. The risk for mental retar-
dation and the difficulty in recognizing the
disease were reasons for introducing neonatal
mass screening programs. Therefore, the most
serious effects of perchlorate might occur dur-
ing the first trimester when the brain is forming
and developing and TH supply is totally depen-
dent on maternal supply of iodine and of thy-
roxine (T4) and triiodothyronine (T3)
To understand the potential impact of per-
chlorate on a gene–environment interaction
model, we need to consider T3 and T4 in a
proper biosynthesis context. TH synthesis and
secretion are exquisitely regulated negative-
feedback systems that involve the hypothala-
mus, pituitary, and thyroid glands. The
hypothalamus secretes thyrotropin-releasing
hormone (TRH), a tripeptide (pyroGlu-
His-Pro) synthesized in the paraventricular
nucleus of the hypothalamus. The TRH, trans-
ported by axons, binds to TRH receptors in
the pituitary thyrotropes, a subpopulation of
pituitary cells that secrete thyroid-stimulating
hormone (TSH). TRH stimulation leads to
release and synthesis of new TSH in thy-
rotropes. The TSH binds to the TSH receptor
in the thyroid gland cells. TSH is the primary
regulator of TH release and secretion. Both
TRH and TSH secretion are negatively regu-
lated by THs: when T4 reaches an adequate
circulating level, the hypothalamus and pitui-
tary reduce their output of TRH and TSH;
they increase their output of TRH and TSH
when the circulating blood level of T4 is low. A
number of thyroid genes, including NIS,
thyroglobulin (Tg ), and thyroid peroxidase
(TPO), are stimulated by TSH and promote
the synthesis of TH (Zoeller 2003).
Iodine is critical to thyroid gland function
and TH synthesis and secretion. The first step
in thyroidal iodine metabolism is the cellular
uptake of iodide from the extracellular fluid.
The thyroidal iodine uptake is tightly regu-
lated by the NIS, an intrinsic plasma mem-
brane protein in the thyroid follicular cells
(Dohán et al. 2003). From the follicular cell,
the iodide moves across the apical membrane,
transported by pendrin protein (Yoshida et al.
2002). The iodide is then delivered to the
cell–colloid interface, where it is oxidized by
TPO and bound to tyrosyl residues in the Tg.
This iodination of specific tyrosines on Tg
yields monoiodinated and diiodinated residues
[monoiodotyrosines (MITs) and diiodo-
tyrosines (DITs)] that are enzymatically cou-
pled to form T4 and T3. The iodinated Tg
containing MIT, DIT, T4, and T3 then is
stored as an extracellular storage polypeptide
in the colloid within the lumen of thyroid fol-
licular cells.
Perchlorate does not undergo metabolism,
but genetic defects of its target, that is, the NIS,
may lead to low iodine uptake in the thyroid
gland, thus depressing production of THs. In
this scenario, exposure to perchlorate may fur-
ther reduce the already low iodide uptake and
decrease production of THs. The combined
effects of perchlorate with a genetic decrease in
THs would hence delineate a population at risk
for decreased thyroid function.
We reviewed published data to identify
genetic factors that might lead to different
responses in people exposed to perchlorate in
the environment. Because perchlorate inhibits
iodide uptake, we focused on the genetic
defects causing CH involving the iodination
process of the THs, particularly a) defects in
iodide transport from circulation into the thy-
roid cell; b) defects in iodide transport from
the thyroid cell to the follicular lumen, often
combined with inner ear deafness [Pendred
syndrome (PDS)]; and c) defects of iodide
organification.
A positive perchlorate discharge test is used
as a diagnostic tool in most of these medical
conditions. A positive diagnosis can be
obtained by administering 1 g potassium per-
chlorate 2 hr after a tracer dose of 131I. In nor-
mal individuals, radioiodide accumulation in
the thyroid gland ends after the administration
of potassium perchlorate, but there is little loss
of the thyroidal radioactivity previously accu-
mulated in the gland. Instead, potassium per-
chlorate causes almost complete discharge of
the unbound fraction of thyroid iodide in indi-
viduals with defects of iodide organification
and with PDS. Therefore, these people could
have different responses to environmental per-
chlorate exposure than normal individuals.
Defects in iodide transport from circula-
tion into the thyroid cell. The NIS is the
plasma membrane glycoprotein that mediates
active iodide uptake into the thyroid follicular
cells. This process is the crucial first step in 
TH biosynthesis. NIS couples the inward
transport of sodium, which occurs in favor of
its electrochemical gradient, to the simultane-
ous inward translocation of iodide against its
electrochemical gradient. Two sodium ions per
iodide ion are translocated into the cells (Dai
et al. 1996; Eskandari et al. 1997). The sodium
gradient that drives iodide uptake is main-
tained by the Na+/K+ ATPase.
Congenital iodide transport deficit (ITD)
is an infrequent autosomic recessive condition
characterized by inability of the thyroid gland
to maintain a concentration gradient of iodide
between the plasma and the thyroid follicular
cell, resulting in hypothyroidism, diffuse or
nodular goiter, and little or no uptake of
radioiodine. The disorder has been linked to a
defect of the NIS. In the absence of a func-
tional NIS molecule, iodide has no access to
the thyroid follicular cells, resulting in
decreased TH biosynthesis and higher circulat-
ing levels of TSH, which in turn stimulates the
morphologic and biochemical changes in the
thyroid that result in development of goiter
(De La Vieja et al. 2000).
The gene coding for human NIS has been
mapped to chromosome 9p12-13.2. It has
15 exons and coding for a glycoprotein of 643
amino acids. NIS is a protein with 13 putative
transmembrane domains, an extracellular
amino terminus, and an intracellular carboxyl
terminus (De La Vieja et al. 2000). About
58 cases of ITD from 33 families have been
reported worldwide. Thirty of 31 cases from
21 families were studied at the molecular level
and had several homozygous or compound
heterozygous mutations of the perchlorate-
sensitive NIS gene. Eleven mutations have
been identified: V59E, G93R, Q267E,
C272X, T354P, G395R, frameshift 515X,
Y531X, G543E, ∆M142-Q323, and ∆A439-
P443 (Fujiwara et al. 1997, 1998, 2000;
Kosugi et al. 1998a, 1998b, 1999, 2002;
Matsuda and Kosugi 1997; Pohlenz et al.
1997, 1998; Tonacchera et al. 2003). The sin-
gle substitution in codon 354 converting from
ACA (Thr) to CCA (Pro) was the most com-
mon mutation detected in 10 patients with
homozygous mutations, and in four patients
with compound heterozygous mutation
(Fujiwara et al. 1997, 1998; Kosugi et al.
1998a, 1998b; Matsuda and Kosugi 1997).
All were Japanese, suggesting that the mutant
NIS T354P is more common in Japan.
However, the frequency of this gene in the
Japanese population is unknown because only
185 healthy people, representing only
370 alleles, have been genotyped.
The frequency of mutations in the NIS
gene in the population is not known.
Heterozygous persons do not express the
phenotype; therefore, NIS gene defects can be
detected only when both alleles are affected.
People with homozygous mutations that cause
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partial loss of function may not be detected
when, under conditions of high iodide intake,
full preservation of iodide concentrating
function is not required to achieve normal hor-
mone synthesis. Therefore, impairment of thy-
roidal iodide concentration requires not only
mutations in both NIS alleles but also defects
that cause virtually complete loss of function.
The therapeutic treatment of ITD patients
consists of L-T4 administration. Some patients
also are supplemented with potassium iodide,
thus underscoring the degree of functional loss
of the mutated NIS. In these persons, perchlo-
rate intake from contaminated sources could
further reduce the functional activity of the
mutated NIS in concentrating iodide in the
thyroid.
Defects in iodide transport from the thyroid
cell to the follicular lumen, often combined
with inner ear deafness (PDS). PDS, an auto-
somal recessive disorder characterized by deaf-
ness and goiter, is the most common cause of
syndromic deafness, accounting for up to 10%
of all hereditary hearing loss (Fraser 1965;
Nilsson et al. 1964). A phenotypic heterogene-
ity exists among affected persons, and thyroid
dysfunction is particularly variable. At least
50% of affected persons have normal circulat-
ing levels of TH, whereas others develop clini-
cal hypothyroidism (Reardon et al. 1999).
Most affected persons demonstrate impaired
iodide organification, as determined by a posi-
tive perchlorate discharge test. Hearing loss in
PDS is prelingual and, in at least 80% of
patients, is associated with structural defects of
the inner ear, including a dilatation of the
vestibular aqueduct and the Mondini defect of
the cochlea (Johnsen et al. 1989). The PDS
gene (SLC26A4) has been linked to chromoso-
mal region 7q31 and contains an open reading
frame of 2,343 bp encompassing 21 exons
(Coyle et al. 1996; Sheffield et al. 1996). The
predicted gene product pendrin is a highly
hydrophobic 780 amino acid protein that
transports chloride and iodide and mediates the
exchange of chloride and formate. In the thy-
roid gland, a disorder in the function of pen-
drin may cause diminished iodide transport
over the apical membrane that results in iodide
remaining in the thyrocyte and a consequent
decrease of organification of iodide. As a result,
iodide accumulates in the cytoplasm and is dis-
charged if thiocyanate or perchlorate is given
(perchlorate discharge test). A decrease in the
amount of radiolabeled iodide over the thyroid
of > 10% is considered positive. At least
85 independent SLC26A4 gene mutations have
been characterized as causing PDS and nonsyn-
dromic deafness, in some cases confirmed by a
normal perchlorate discharge test (Adato et al.
2000; Blons et al. 2004; Bogazzi et al. 2000,
2004; Campbell et al. 2001; Coucke et al.
1999; Coyle et al. 1998; Everett et al. 1997;
Fugazzola et al. 2000; Kopp et al. 1999; Li et al.
1998; Lopez-Bigas et al. 2002; Namba et al.
2001; Park et al. 2003; Prasad et al. 2004;
Reardon et al. 2000; Scott et al. 2000; Tekin
et al. 2003; Tsukamoto et al. 2003; Usami et al.
1999; Van Hauwe et al. 1998; Yong et al.
2001). Although these mutations are distrib-
uted throughout the coding sequence, having
been identified in 19 of the 21 exons, the spec-
trum of mutations appears to show geographic
differences. In Caucasian patients, the L236P,
T416P, and IVS8+1G > A mutations account
for nearly half of all SLC26A4 mutant alleles,
whereas in Japanese patients, these mutations
are rare (Campbell et al. 2001; Tsukamoto
et al. 2003). By contrast, H723R and ISV7–2A
> G are the prevalent alleles accounting for
most observed SLC26A4 mutations in Korean
and Japanese studies (Park et al. 2003;
Tsukamoto et al. 2003). Some researchers have
suggested that the frequency of these mutations
could represent a founder effect rather than
mutational hot spots.
A disorder in the function of pendrin will
cause a diminished iodide transport over the
apical membrane, which causes iodide to
remain in the thyrocyte. Intake of perchlorate
from a contaminated source may cause dis-
charge of iodide from the thyrocyte, further
exacerbating the organification defect, with
resulting decrease of TH synthesis.
Moreover, at present, it is not known
whether perchlorate will affect the function of
the normal pendrin protein to transport iodide.
Molecular studies addressing whether perchlo-
rate may act on iodide transport through inhi-
bition of the pendrin protein in a fashion
similar to the NIS are needed and welcomed.
Defects in iodide organification. Iodide
organification is the process by which iodine is
oxidized and bound to thyrosine residue in
Tg. Thyroid iodide organification disorder
represents a group of defects characterized by
discharge of substantial percentage of labeled
iodide from the thyroid after administration of
perchlorate (perchlorate discharge test) or
thiocyanate. This discharge indicates a defect
in converting accumulated iodide to organi-
cally bound iodine. The discharge may be par-
tial or complete, thus defining partial or total
defects. Partial iodide organification defects
(PIODs) are characterized by release of < 50%
of the accumulated radioiodine. Total iodide
organification defects (TIODs) are character-
ized by release of > 90% of the accumulated
radioiodine.
Iodination of the tyrosine residue is cata-
lyzed by the membrane-bound thyroperoxidase
(TPO). However, the oxidation of iodine
requires hydrogen peroxide synthesized outside
the thyroid follicular cell at the apical border
catalyzed by the thyroid complex. Recently,
two proteins of this complex, DUOX1 (also
known as THOX1) and DUOX2 (also known
as THOX2), have been identified (De Deken
et al. 2000; Dupuy et al. 1999). The DUOX1
and DUOX2 genes are co-localized on the
15q15.3 chromosome and code for proteins of
1,551 and 1,548 amino acids, respectively. The
DUOX1 and DUOX2 structure includes
seven transmembrane-spanning domains, three
NADPH- and one FAD-binding site, and
2EF-hand motifs. During the past three
decades, few cases of thyroidal hydrogen perox-
ide have been described, but the molecular
bases of these defects have just recently been
investigated. Moreno et al. (2002) reported
mutations in the DUOX2 gene, resulting in
premature stop codon, in four CH patients
with unexplained iodide organification defects.
One patient with permanent CH and TIOD
carried a homozygous substitution, whereas
three patients with temporary CH and PIOD
carried heterozygous mutations that cause
premature termination signal.
Lack of or insufficient activity of the
DUOX2 protein diminishes hydrogen per-
oxide production, resulting in decreased activ-
ity of TPO and accumulation of iodide in the
thyrocyte. Intake of environmental perchlo-
rate, which inhibits iodine inflow, also may
cause discharge of unbound iodine, further
deteriorating the iodine organification process.
Under oxidative conditions, TPO catalyzes
the coupling of iodotyrosines to iodothyronine
residue in Tg. Thyroperoxidase is a glycosylated
hemoprotein encoded by the TPO gene located
on chromosome 2p25. The gene contains
17 exons coding for a protein of 933 amino
acids. The protein has a transmembrane helix
with a large extracellular N-terminal part con-
taining a heme group. TPO defects are believed
to be among the most frequent causes of abnor-
malities in thyroid iodide organification defect
causing goitrous CH. TPO activity is not
detectable in thyroid tissue of patients with
TIOD. Absence of TPO activity implicates the
inability to iodinate tyrosine residue in Tg and
to couple these residues to form THs, mainly
T4 and some T3 and rT3 (reverse T3) Inactivat-
ing mutations in both TPO alleles have been
found in patients with CH caused by TIOD.
With use of a variety of molecular techniques
for mutation deletion, 36 mutations have now
been defined for TPO. These include frameshift
mutations caused by nucleotide insertion or
deletion, as well as missense, nonsense, and
splice site mutations (Abramowicz et al. 1992;
Ambrugger et al. 2001; Bakker et al. 2000;
Bikker et al. 1994, 1995, 1997; Kotani et al.
2001; Nascimento et al. 2003; Niu et al. 2002;
Pannain et al. 1999; Rivolta et al. 2003; Santos
et al. 1999; Umeki et al. 2002, 2004; Wu et al.
2002). The first reported mutation was a
homozygous GGCC insertion in exon 8 of the
TPO gene. The resulting frameshift generates a
stop codon in exon 9, which results in a grossly
truncated protein with no expected activity
(Abramowicz et al. 1992). In a Dutch study of
Genetic factors and perchlorate
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45 patients from 40 families with CH caused
by TIOD, the GGCC insertion in exon 8 at
nucleotide position 1287 was the most com-
mon mutation found (Bakker et al. 2000). It
was detected in 36% of the investigated TPO
alleles and in 51% of the families investigated
either in a homozygous or a compound
heterozygous fashion. In this study, mutations
in both TPO alleles were found in 29 families:
for 13 families in a homozygous fashion and
for 16 families in a compound heterozygous
fashion. A total of 16 different mutations were
found, including 8 novel mutations: 6 frame-
shift mutations, 6 missense mutations, 3 splice
site mutations, and 1 nonsense mutation.
Most of these mutations occurred in exon 8,
9, or 10, which encode for the active part of
the enzyme involved in the heme binding. In
one patient with classic TIOD, a homozygous
deletion in exon 14 appeared to have resulted
from partial maternal isodisomy of the short
arm of chromosome 2 carrying the defective
TPO gene (Bakker et al. 2001). In some
patients alternative splicing would generate a
partially active form of the enzyme. In others an
early termination signal would prevent transla-
tion of the fully active protein (Abramowicz
et al. 1992; Bikker et al. 1994, 1995;
Mangklabruks et al. 1991; Santos et al. 1999).
Umeki et al. (2002) described 2 novel muta-
tions in the TPO gene, R665W and G771R, in
exons 11 and 13, respectively. The former was
found in the patient’s father (heterozygous) and
the latter in her mother, also heterozygous. No
TPO activity was detectable with cells trans-
fected with mutated mRNAs. Moreover, the
mutated TPO proteins showed abnormal cellu-
lar localization, exhibiting immunofluorescence
only in the intracellular structure. Therefore,
the loss of apical membrane localization of the
mutated TPO was the main cause for the
iodide organification defect.
PIODs also can be caused by disorders in
TPO. In an investigation of TPO mutations in
five families with PIOD, Nascimento et al.
(2003) found a compound heterozygous muta-
tion in three patients from one family inherited
from both heterozygous parents. In the other
four families, they found only heterozygous
TPO mutations or polymorphisms, suggesting
the translated protein could be partially inac-
tive. Recently, PIOD caused by TPO gene was
diagnosed in three siblings (Kotani et al.
2003). The three siblings with goiter and
latent-to-mild hypothyroidism had a com-
pound heterozygous mutation for a missense
mutation (G1687T) and a deletion in exon 10
(1808-13del), resulting in a produced protein
with two deleted amino acids ∆D574-L4575.
From the expression studies, the mutated
∆D574-L4575–TPO synthesized THs to
some extent (Kotani et al. 2003).
A common feature of patients with thy-
roid organification disorders syndrome is the 
discharge of iodine from the thyroid after
administration of perchlorate. The level of
perchlorate administrated in the diagnostic
test is higher than the reported level of conta-
minated sources. However, it is biologically
plausible that cumulative ingestion of per-
chlorate through a contaminated source may
cause some degree of iodine discharge from
thyrocytes. In populations with partial activ-
ity of the TPO enzyme, exposure to high
enough levels of environmental perchlorate
could cause unbound iodide discharge; there-
fore, less iodine will be available for bio-




Many studies have attempted to provide use-
ful information on the dose–response relation
of perchlorate-related health effects. Several
ecologic studies have compared thyroid func-
tion in newborns using T4 and TSH screen-
ing data in infants born to mothers in areas
with different perchlorate exposure. However,
these studies yielded contradictory results.
Brechner et al. (2000) found higher TSH in
newborns in Yuma, Arizona, which has high
perchlorate exposure, than in Flagstaff,
Arizona, which has lower exposure. However,
whether perchlorate exposure caused the
observed TSH effect cannot be addressed
because of the lack of direct perchlorate meas-
urement in the study. By contrast, F.X. Li
et al. (2000) and Z. Li et al. (2000) found no
association in Nevada newborns between low
T4 and TSH levels and perchlorate exposure.
A limitation of these studies is that the inves-
tigators did not collect data on individual
exposure to perchlorate and on iodine intake
levels. In a population-based ecologic study
using California Newborn Screening Program
data, Schwartz (2001) claimed to identify a
significant dose–response association between
perchlorate exposure and T4, and an associa-
tion of perchlorate exposure and being a pre-
sumptive positive for CH. These data
contrast with a previous ecologic analysis
(Lamm and Doemland 1999) that found no
increase of CH incidence in California and
Nevada counties with perchlorate levels of
4–16 µg/L in drinking water supplies.
Crump et al. (2000) conducted a study in
three proximate cities in northern Chile that
had different concentrations of perchlorate in
tap water, involving 162 school-age children
and 9,784 newborns. These authors found no
alteration of thyroid function or incidence of
CH in Taltal, Chile, where the tap water con-
tained 100–120 µg/L perchlorate, compared
with two other regions of Chile with low or
no perchlorate in the water. However, the data
also showed high levels of urine iodine, indi-
cating that iodine intake in the population was
very high, possibly overcoming the inhibitory
effect of perchlorate on thyroid function.
To establish the dose response in humans
for the perchlorate inhibition of thyroidal
iodide uptake and the short-term effects on
circulating TH, Greer et al. (2002) gave per-
chlorate in drinking water at 0.007, 0.02, 0.1,
or 0.5 mg/kg per day to 37 male and female
volunteers for 14 days. In 24 participants 8-
and 24-hr measurements of thyroidal 123I
uptake (RAIU) were performed before expo-
sure, on exposure days 2 and 14, and 15 days
postexposure. Results from the study indicated
a true no-effect level of perchlorate of 5.2 or
6.4 µg/kg/day for RAIU. Considering that a
70 kg adult drinks 2 L of water per day, this
dose would be ingested if the drinking water
contained 182–224 µg/L. In addition, the
dose of 0.5 mg/kg/day taken for 14 days did
not produce changes in circulating levels of T4
or TSH, suggesting that short-term consump-
tion of perchlorate levels of 17.5 mg/L in
drinking water would not affect circulating
levels of THs. The authors suggested that this
failure of perchlorate to influence circulating
levels of TH resulted from the storage capacity
of the normal adult thyroid gland, which con-
tains unreleased stored hormones lasting for
several months. However, as pointed out by
Zoeller (2003), the case may be different for a
late gestation fetus or neonate, where the esti-
mated intrathyroidal amount of hormone
stored is less than that required for 1 day
(Van den Hove et al. 1999; Vulsma et al.
1989). Thus, the concentration of perchlorate
sufficient to reduce thyroidal iodine uptake in
a fetus or neonate may be sufficient to pro-
duce a significant decrement in circulating lev-
els of TH. The fetal thyroid gland obtains
iodide for its own TH synthesis from the
maternal circulation through the placenta.
Placental transfer of perchlorate has been
reported in guinea pig (Postel 1957). In
human, whether perchlorate crosses from the
mother to the fetus during pregnancy is not
known. However, this placental transfer could
be biologically plausible because expression of
the NIS has been reported in human placenta
(Bidart et al. 2000). Moreover, perchlorate
may concentrate in milk because the NIS pro-
tein is induced in lactating breast tissue by
prolactin (Tazebay et al. 2000). Perchlorate
might decrease iodide uptake into milk, thus
reducing the sole source of iodine to the
infant. Differently from adults, who most
likely can recover from transient hypo-
thyroidism without permanent health conse-
quences, a short period of TH insufficiency
may produce permanent neurologic deficits in
children (Van Vliet 1999). The study of no-
effect level (Greer et al. 2002) was conducted
in healthy adults with normal iodine intake,
and it is debatable whether 14 days is suffi-
cient time to illustrate perchlorate effect on
Scinicariello et al.
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humans. This no-effect level most likely
would be lower in populations with genetic
defects causing CH and in populations with
lower iodine uptake. The Third National
Health and Nutrition Examination 
Survey (NHANES III), conducted during
1988–1994, found that the percentages of
males and females with urinary iodine concen-
trations < 5 µg/dL were substantially higher in
every age category than in the 1971–1974 sur-
vey (Hollowell et al. 1998). In pregnant
women, these percentages were 6.9% in
NHANES III and 1.0% in NHANES I
(Hollowell et al. 1998). The overall decline in
the last few decades raises concern that a fairly
large number of people in the United States
may lack adequate iodine intake.
Conclusions
Exposure to perchlorate, which inhibits iodine
uptake, has the biologic potential to cause
hypothyroidism and, in pregnant women,
severely damage the fetus and the newborn.
NHANES III data suggest that 4.3% of the
U.S. population may be subclinically hypo-
thyroid (Hollowell et al. 2002). CH affects
about 1 in 3,000 to 1 in 4,000 infants and in
about 15% of cases may result from a defect of
thyroid hormonogenesis, mostly inherited in
an autosomal recessive fashion (Vulsma and
de Vijlder 2000). Such defects may result
from abnormalities in several steps involved in
TH synthesis. Our literature review identified
possible homozygous or compound hetero-
zygous mutations of genes involved in thyroid
iodine synthesis that cause hypothyroidism
that could be used to define a potential sus-
ceptible population to perchlorate exposure.
In a Mendelian fashion, the number of carriers
of heterozygous mutated gene causing CH
would be higher than the number of the
reported CH cases. Given the logical connec-
tion between perchlorate, diminished iodine
uptake, hypothyroidism, and thyroid-related
health effects, people exhibiting heterozygous
or homozygous genetic mutations in genes
involved in the TH synthesis, especially in a
milieu of low iodine uptake, can reasonably be
expected to be more susceptible than people
who show no genetic variability to the effects
of perchlorate. Several studies based on T4 and
TSH screening data in infants born to moth-
ers in areas with different perchlorate exposure
mostly have found no increase in hypo-
thyroidism incidence. However, these studies
lacked estimates of individual perchlorate
exposure, as well as estimates of individual
iodine uptake. The only study that included
iodine values showed no significant association
between perchlorate and hypothyroidism.
However, it showed high urinary iodide, sug-
gesting the high iodine uptake could easily
have upset the inhibition factor of the perchlo-
rate. We conclude that future epidemiologic
and population-based studies as well as no-
effect studies concerning the link between
human disease and environmental perchlorate
exposure should consider among their vari-
ables the genetic makeup of the participants,
actual perchlorate exposure levels, and individ-
ual iodine uptake and excretion levels.
REFERENCES
Abramowicz MJ, Targovnik H, Varela V, Cochaud P, Krawiec L,
Pisarev MA, et al. 1992. Identification of a mutation in the
coding sequence of the human thyroid peroxidase gene
causing congenital goiter. J Clin Invest 90:1200–1204.
Adato A, Raskin L, Petit C, Bonne-Tamir B. 2000. Deafness hetero-
geneity in a Druze isolate from the Middle East: novel OTOF
and PDS mutations, low prevalence of GJB2 35delG muta-
tion and indication for a new DFNB locus. Eur J Hum Genet
8:437–442.
Ambrugger P, Stoeva I, Biebermann H, Torresani T, Leitner C,
Gruters A. 2001. Novel mutations of the thyroid peroxidase
gene in patients with permanent congenital hypothyroidism.
Eur J Endocrinol 145:19–24.
Anbar M, Guttmann S, Lweitus Z. 1959. The mode of action of
perchlorate ions on the iodine uptake of the thyroid gland.
Int J Appl Radiat Isot 7:87–96.
Bakker B, Bikker H, Hennekam RC, Lommen EJ, Schipper MG,
Vulsma T, et al. 2001. Maternal isodisomy for chromosome
2p causing severe congenital hypothyroidism. J Clin
Endocrinol Metab 86:1164–1168.
Bakker B, Bikker H, Vulsma T, de Randamie JS, Wiedijk BM, de
Vijlder JJM. 2000. Two decades of screening for congeni-
tal hypothyroidism in the Netherlands: TPO gene muta-
tions in total iodide organification defects (an update).
J Clin Endocrinol Metab 85:3708–3712.
Bidart JM, Lacroix L, Evain-Brion D, Caillou B, Lazar V,
Frydman R, et al. 2000. Expression of Na+/I- symporter and
Pendred syndrome genes in trophoblast cells. J Clin
Endocrinol Metab 85:4367–4372.
Bikker H, Baas F, de Vijlder JJM. 1997. Molecular analysis of
mutated thyroid peroxidase detected in patients with total
iodide organification defects. J Clin Endocrinol Metab
82:649–653.
Bikker H, Den Hartog MT, Baas F, Gons MH, Vulsma T, de Vijlder
JJM. 1994. A 20 base pair duplication in the human thyroid
peroxidase gene results in a total iodide organification
defect and congenital hypothyroidism. J Clin Endocrinol
Metab 79:248–252.
Bikker H, Vulsma T, Baas F, de Vijlder JJM. 1995. Identification
of five novel inactivating mutation in the human thyroid
peroxidase gene by denaturing gradient gel electrophore-
sis. Hum Mutat 6:9–16.
Blons H, Feldmann D, Duval V, Messaz O, Denoyelle F, Loundon
N, et al. 2004. Screening of SLC26A4 (PDS) gene in Pendred’s
syndrome: a large spectrum of mutations in France and
phenotypic heterogeneity. Clin Genet 66:333–340.
Bogazzi F, Raggi F, Ultimieri F, Campomori A, Cosci C, Berrettini
S, et al. 2000. A novel mutation in the pendrin gene associ-
ated with Pendred’s syndrome. Clin Endocrinol 52:279–285.
Bogazzi F, Russo D, Raggi F, Ultimieri F, Berrettini S, Forli F, et al.
2004. Mutations in the SLC26A4 (pendrin) gene in patients
with sensorineural deafness and enlarged vestibular aque-
duct. J Endocrinol Invest 27:430–435.
Brechner R, Parkhurst G, Humble W, Brown M, Herman W. 2000.
Ammonium perchlorate contamination of Colorado River
drinking water is associated with abnormal thyroid function
in newborns in Arizona. J Occup Environ Med 42:777–782.
Campbell C, Cucci RA, Prasad S, Green GE, Edeal JB, Galer CE,
et al. 2001. Pendred syndrome, DFNB4, and PDS/SLC26A4:
identification of eight novel mutations and possible geno-
type–phenotype correlations. Hum Mutat 17:403–411.
Coucke PJ, Van Hauwe P, Everett LA, Demirhan O, Kabakkaya Y,
Dietrich NL, et al. 1999. Identification of two different muta-
tions in the PDS gene in an inbred family with Pendred
syndrome. J Med Genet 36:475–477.
Coyle B, Coffey R, Armour JA, Gausden E, Hochberg Z,
Grossman A, et al. 1996. Pendred syndrome (goitre and sen-
sorineural hearing loss) maps to chromosome 7 in the
region containing the nonsyndromic deafness gene DFNB4.
Nat Genet 12:421–423.
Coyle B, Reardon W, Herbrick JA, Tsui LC, Gausden E, Lee J,
et al. 1998. Molecular analysis of the PDS gene in Pendred
syndrome. Hum Mol Genet 7:1105–1112.
Crump C, Michaud P, Tellez R, Reyes C, Gonzalez G, Montgomery
EL, et al. 2000. Does perchlorate in drinking water affect thy-
roid function in newborns or school-age children? J Occup
Environ Med 42:603–612.
Dai G, Levy O, Carrasco N. 1996. Cloning and characterization
of the thyroid iodide transporter. Nature 379:458–460.
De Deken X, Wang D, Many MC, Costagliola S, Libert F, Vassart
G, et al. 2000. Cloning of two human thyroid cDNAs encoding
new members of the NADPH oxidase family. J Biol Chem
275:23227–23233.
De la Vieja A, Dohán O, Levy O, Carrasco N. 2000. Molecular
analysis of the sodium/iodide symporter: impact on thyroid
and extrathyroid pathophysiology. Physiol Rev 80:1083–1095.
Dohán O, De la Vieja A, Paroder V, Riedel C, Artani M, Reed M,
et al. 2003. The sodium/iodide symporter (NIS): characteriza-
tion, regulation and medical significance. Endocr Rev
24:48–77.
Dupuy C, Ohayon R, Valent A, Noel-Hudson MS, Deme D, Virion
A. 1999. Purification of a novel flavoprotein involved in the
thyroid NADPH oxidase. Cloning of the porcine and human
cDNAs. J Biol Chem 274:37265–37269.
Eichler O, Hackenthal E. 1962. [Secretion and metabolism of per-
chlorate measured with 36ClO4.] Naunyn Schmiedebergs
Arch Exp Pathol Pharmakol 243:554–565.
Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N.
1997. Thyroid Na+/I symporter. Mechanism, stoichiometry,
and specificity. J Biol Chem 272:27230–27238.
Everett LA, Glaser B, Beck JC, Idol JR, Buchs A, Heyman M, et al.
1997. Pendred syndrome is caused by mutations in a puta-
tive sulphate transporter gene (PDS). Nat Genet 17:411–422.
Fraser GR. 1965. Association of congenital deafness with goiter
(Pendred’s syndrome). Ann Hum Genet 28:201–249.
Fugazzola L, Mannavola D, Cerutti N, Maghnie M, Pagella F,
Bianchi P, et al. 2000. Molecular analysis of the Pendred’s
syndrome gene and magnetic resonance imaging studies of
the inner ear are essential for the diagnosis of true
Pendred’s syndrome. J Clin Endocrinol Metab 85:2469–2475.
Fujiwara H, Tatsumi K, Miki K, Harada T, Miyai K, Taki S, et al.
1997. Congenital hypothyroidism caused by a mutation in
the Na+/I– symporter. Nature Gen 16:124–125.
Fujiwara H, Tatsumi K, Miki K, Harada T, Okada S, Nose O, et al.
1998. Recurrent T354P mutation of the Na+/I symporter in
patients with iodide transport defect. J Clin Endocrinol
Metab 83:2940–2943.
Fujiwara H, Tatsumi K, Tanaka S, Kimura M, Nose O, Amino N.
2000. A novel V59E missense mutation in the sodium iodide
symporter gene in a family with iodide transport defect.
Thyroid 10:471–474.
Greer MA, Goodman G, Pleus RC, Greer SE. 2002. Health effects
assessment for environmental perchlorate contamination:
the dose-response for inhibition of thyroidal radioiodine
uptake in humans. Environ Health Perspect 110:927–937.
Greer MA, Stott AK, Milne KA. 1966. Effects of thiocyanate,
perchlorate and other anions on thyroidal iodine metabo-
lism. Endocrinology 79:237–247.
Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter
EW, Spencer CA, et al. 2002. Serum TSH, T(4), and thyroid
antibodies in the United States population (1988 to 1994):
National Health and Nutrition Examination Survey
(NHANES III). J Clin Endocrinol Metab 87:489–499.
Hollowell JG, Staehling NW, Hannon WH, Flanders DW, Gunter
EW, Maberly GF, et al. 1998. Iodine nutrition in the United
States. Trends and public health implications: iodine excre-
tion data from National Health and Nutrition Examination
Surveys I and III (1971-1974 and 1988-1994). J Clin
Endocrinol Metab 83:3401-3408.
Johnsen T, Videbaek H, Olsen KP. 1989. CT-scanning of the
cochlea in Pendred’s syndrome. Clin Otolaryngol 14:389–393.
Kelada SN, Eaton DL, Wang SS, Rothman NR, Khoury MJ. 2003.
The role of genetic polymorphisms in environmental
health. Environ Health Perspect 111:1055–1064.
Kirk AB, Smith EE, Tian K, Anderson TA, Dasgupta PK. 2003.
Perchlorate in milk. Environ Sci Technol 37:4979–4981.
Kopp P, Arseven OK, Sabacan L, Kotlar T, Dupuis J, Cavaliere H,
et al. 1999. A novel mutation in the sodium/iodide symporter
gene in the largest family with iodide transport defect.
J Clin Endocrinol Metab 84:336–341.
Kosugi S, Bhayana S, Dean HJ. 1999. A novel mutation in the
sodium/iodide symporter gene in the largest family with iodide
transport defect. J Clin Endocrinol Metab 84:3248–3253.
Kosugi S, Inoue S, Matsuda A, Jhiang SM. 1998b. Novel, mis-
sense and loss-of-function mutations in the sodium/iodide
Scinicariello et al.
1484 VOLUME 113 | NUMBER 11 | November 2005 • Environmental Health Perspectives
symporter gene causing iodide transport defect in three
Japanese patients. J Clin Endocrinol Metab 83:3373–3376.
Kosugi S, Okamoto H, Tamada A, Sanchez-Franco F. 2002. A
novel peculiar mutation in the sodium/iodide symporter gene
in Spanish siblings with iodide transport defect. J Clin
Endocrinol Metab 87:3830–3836.
Kosugi S, Sato Y, Matsuda A, Ohyama Y, Fujieda K, Inomata H,
et al. 1998a. High prevalence of T354P sodium/iodide sym-
porter gene in Spanish siblings with iodide transport
defect. J Clin Endocrinol Metab 83:4123–4129.
Kotani T, Umeki K, Kawano J, Suganuma T, Hishinuma A, Ieiri T,
et al. 2003. Partial iodide organification defect caused by a
novel mutation of the thyroid peroxidase gene in three sib-
lings. Clin Endocrinol 59:198–206.
Kotani T, Umeki K, Yamamoto I, Ohtaki S, Adachi M, Tachibana K.
2001. Iodide organification defects resulting from cosegre-
gation of mutated and null thyroid peroxidase alleles. Mol
Cell Endocrinol 182:61–68.
Lamm SH, Doemland M. 1999. Has perchlorate in drinking
water increased the rate of congenital hypothyroidism?
J Occup Environ Med 41:409–411.
Li FX, Byrd DM, Deyhle GM, Sesser DE, Skeels MR, Katkowsky
SR, et al. 2000. Neonatal thyroid stimulating hormone level
and perchlorate in drinking water. Teratology 62:429–431.
Li XC, Everett LA, Lalwani AK, Desmukh D, Friedman TB, Green
ED, et al. 1998. A mutation in PDS causes non-syndromic
recessive deafness. Nat Genet 18:215–217.
Li Z, Li FX, Byrd D, Deyhle GM, Sesser DE, Skeels MR, et al.
2000. Neonatal thyroxine level and perchlorate in drinking
water. J Occup Environ Med 42:200–205.
Lopez-Bigas N, Melchionda S, de Cid R, Grifa A, Zelante L,
Govea N, et al. 2002. Identification of five new mutations of
PDS/SLC26A4 in Mediterranean families with hearing
impairment. Hum Mutat 20:77–78.
Mangklabruks A, Billerbeck AE, Wajchenberg B, Knobel M, Cox
NJ, DeGroot LJ, et al. 1991. Genetic linkage studies of thyroid
peroxidase (TPO) gene in families with TPO deficiency. J Clin
Endocrinol Metab 72:471–476.
Matsuda A, Kosugi S. 1997. A homozygous missense mutation
of the sodium/iodide symporter gene causing iodide trans-
port defect. J Clin Endocrinol Metab 82 3966–3971.
Moreno JC, Bikker H, Kempers MJ, van Trotsenburg AS, Baas F,
de Vijlder JJ, et al. 2002. Inactivating mutations in the gene
for thyroid oxidase 2 (THOX2) and congenital hypothyroidism.
N Engl J Med 347:95–102.
Motzer WE. 2001. Perchlorate: problems, detection, and solu-
tions. Environ Forensics 2:301–311.
Namba A, Abe S, Shinkawa H, Kimberling WJ, Usami SI. 2001.
Genetic features of hearing loss associated with ear anom-
alies: PDS and EYA1 mutation analysis. J Hum Genet
46:518–521.
Nascimento AC, Guedes DR, Santos CS, Knobel M, Rubio IG,
Medeiros-Neto G. 2003. Thyroperoxidase gene mutations
in congenital goitrous hypothyroidism with total and par-
tial iodide organification defect. Thyroid 13:1145–1151.
Nilsson LR, Borgfors N, Gamstorp I, Holst HE, Liden G. 1964.
Nonendemic goitre and deafness. Acta Paediatr 53:117–131.
Niu DM, Hwang B, Chu YK, Liao CJ, Wang PL, Lin CY. 2002. High
prevalence of a novel mutation (2268 insT) of the thyroid per-
oxidase gene in Taiwanese patients with total iodide organi-
fication defect and evidence for a founder effect. J Clin
Endocrinol Metab 87:4208–4212.
Pannain S, Weiss RE, Jackson CE, Dian D, Beck JC, Sheffield
VC, et al. 1999. Two different mutations in the thyroid per-
oxidase gene of a large inbred Amish kindred: power and
limits of homozygosity mapping. J Clin Endocrinol Metab
84:1061–1071.
Park HJ, Shaukat S, Liu XZ, Hahn SH, Naz S, Ghosh M, et al.
2003. Origins and frequencies of SLC26A4 (PDS) mutations
in east and south Asians: global implications for the epi-
demiology of deafness. J Med Genet 40:242–248.
Pohlenz J, Medeiros-Neto G, Gross JL, Silveira SP, Knobel M,
Refetoff, S. 1997. Hypothyroidism in a Brazilian kindred due
to iodide trapping defect caused by a homozygous muta-
tion in the sodium/iodide symporter gene. Biochem
Biophys Res Commun 240:488–491.
Pohlenz J, Rosenthal IM, Weiss RE, Jhiang SM, Burant C,
Refetoff S. 1998. Congenital hypothyroidism due to muta-
tions in the sodium/iodide symporter. Identification of a
nonsense mutation producing a downstream cryptic 3’
splice site. J Clin Invest 101:1028–1035.
Postel S. 1957. Placental transfer of perchlorate and triiodothy-
ronine in the guinea pig. Endocrinology 60:53–66.
Prasad S, Kolln KA, Cucci RA, Trembath RC, Van Camp G, Smith
RJ. 2004. Pendred syndrome and DFNB4-mutation screen-
ing of SLC26A4 by denaturing high-performance liquid
chromatography and the identification of eleven novel
mutations. Am J Med Genet 124A:1–9.
Reardon W, Coffey R, Chowdhury T, Grossman A, Jan H,
Britton K, et al. 1999. Prevalence, age of onset, and natural
history of thyroid disease in Pendred syndrome. J Med
Genet 36:595–598.
Reardon W, O’Mahoney CF, Trembath R, Jan H, Phelps PD.
2000. Enlarged vestibular aqueduct: a radiological marker
of Pendred syndrome, and mutation of the PDS gene. Q J
Med 93:99–104.
Rivolta CM, Esperante SA, Gruneiro-Papendieck L, Chiesa A,
Moya CM, Domene S, et al. 2003. Five novel inactivating
mutations in the thyroid peroxidase gene responsible for
congenital goiter and iodide organification defect. Hum
Mutat 22:259.
Santos CL, Bikker H, Rego KGM, Nascimento AC, Tambascia
M, De Vijlder JJM, et al. 1999. A novel mutation in the TPO
gene in goitrous hyperthyroid patients with iodide organifi-
cation defect. Clin Endocrinol 51:165–172.
Schwartz J. 2001. Gestational Exposure to Perchlorate Is
Associated with Measures of Decreased Thyroid Function
in a Population of California Neonates [Master’s thesis].
Berkeley, CA:University of California Berkeley.
Scott DA, Wang R, Kreman TM. 2000. Functional differences of
the PDS gene product are associated with phenotypic
variation in patients with Pendred syndrome and non-syn-
dromic hearing loss (DFNB4). Hum Mol Genet 9:1709–1715.
Sheffield VC, Kraiem Z, Beck JC, Nishimura D, Stone EM,
Salameh M, et al. 1996. Pendred syndrome maps to chro-
mosome 7q21–34 and is caused by an intrinsic defect in
thyroid iodine organification. Nat Genet 12:424–426.
Smith PN, Theodorakis CW, Anderson TA, Kendall RJ. 2001.
Preliminary assessment of perchlorate in ecological recep-
tors at the Longhorn Army Ammunition Plant (LHAAP),
Karnack, Texas. Ecotoxicology 10:305–313.
Soldin OP, Braverman LE, Lamm SH. 2001. Perchlorate clinical
pharmacology and human health: a review. Ther Drug
Monit 23:316–331.
Stanbury JB, Wyngaarden JB. 1952. Effect of perchlorate on
the human thyroid gland. Metabolism 1:533–539.
Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH,
et al. 2000. The mammary gland iodide transporter is
expressed during lactation and in breast cancer. Nat Med
6:871–878.
Tekin M, Akcayoz D, Comak E, Bogoclu G, Duman T, Fitoz S, et al.
2003. Screening the SLC26A4 gene in probands with deaf-
ness and goiter (Pendred syndrome) ascertained from a
large group of students of the schools for the deaf in Turkey.
Clin Genet 64:371–374.
Tonacchera M, Agretti P, De Marco G, Elisei R, Perri A,
Ambrogini E, et al. 2003. Congenital hypothyroidism due to a
new deletion in the sodium/iodide symporter protein. Clin
Endocrinol 59:500–506.
Tonacchera M, Pinchera A, Dimida A, Ferrarini E, Agretti P,
Vitti P, et al. 2004. Relative potencies and additivity of per-
chlorate, thiocyanate, nitrate, and iodide on the inhibition
of radioactive iodide uptake by the human sodium iodide
symporter. Thyroid 12:1012–1019.
Tsukamoto K, Suzuki H, Harada D, Namba A, Abe S, Usami S.
2003. Distribution and frequencies of PDS (SLC26A4) muta-
tions in Pendred syndrome and nonsyndromic hearing loss
associated with enlarged vestibular aqueduct: a unique
spectrum of mutations in Japanese. Eur J Hum Genet
11:916–922.
Umeki K, Kotani T, Kawano J, Suganuma T, Yamamoto I,
Aratake Y, et al. 2002. Two novel missense mutations in the
thyroid peroxidase gene, R665W and G771R, result in a
localization defect and cause congenital hypothyroidism.
Eur J Endocrinol 146:491–498.
Umeki K, Yamamoto I, Yukizane S, Kotani T. 2004. Congenital
hypothyroidism caused by a unique thyroid peroxidase allele
containing two mutations, C1708T and C2737T. J Pediatr
Endocrinol Metab 17:231–234.
Usami S, Abe S, Weston MD, Shinkawa H, Van Camp G,
Kimberling WJ. 1999. Non-syndromic hearing loss associated
with enlarged vestibular aqueduct is caused by PDS muta-
tions. Hum Genet 104:188–192.
van den Hove MF, Beckers C, Devlieger H, de Zegher F, De
Nayer P. 1999. Hormone synthesis and storage in the thy-
roid of human preterm and term newborns: effect of thy-
roxine treatment. Biochimie 81:563–570.
Van Hauwe P, Everett LA, Coucke P, Scott DA, Kraft ML, Ris-
Stalpers C, et al. 1998. Two frequent missense mutations in
Pendred syndrome. Hum Mol Genet 7:1099–1104.
van Vliet G. 1999. Neonatal hypothyroidism: treatment and out-
come. Thyroid 9:79–84.
Vulsma T, de Vijlder JIM. 2000. Thyroid disease in newborns,
infants and children. In: Oxford Textbook of Endocrinology
and Diabetes (Wass JAH Shalet SM, eds). Oxford,
UK:Oxford University Press, 532–544.
Vulsma T, Gons MH, de Vijlder JJ. 1989. Maternal-fetal transfer of
thyroxine in congenital hypothyroidism due to a total organi-
fication defect or thyroid agenesis. N Engl J Med 321:13–16.
Wolff J. 1998. Perchlorate and the thyroid gland. Pharmacol
Rev 50:89–105.
Wu JY, Shu SG, Yang CF, Yang CF, Lee CC, Tsai FJ, et al. 2002.
Mutation analysis of thyroid peroxidase gene in Chinese
patients with total iodide organification defect: identification
of five novel mutations. J Endocrinol 172:627–635.
Wyngaarden JB, Stanbury JB, Rapp B. 1953. The effects of
iodide, perchlorate, thiocyanate and nitrate administration
upon the iodide concentrating mechanism of the rat thyroid.
Endocrinology 52:568–574.
Yong AM, Goh SS, Zhao Y, Eng PH, Koh LK, Khoo DH. 2001. Two
Chinese families with Pendred’s syndrome: radiological
imaging of the ear and molecular analysis of the pendrin
gene. J Clin Endocrinol Metab 86:3907–3911.
Yoshida A, Taniguchi S, Hisatome I, Royaux IE, Green ED, Kohn
LD, et al. 2002. Pendrin is an iodide-specific apical porter
responsible for iodide efflux from thyroid cells. J Clin
Endocrinol Metab 87:3356–3361.
Zoeller RT. 2003. Challenges confronting risk analysis of poten-
tial thyroid toxicants. Risk Anal 23:143–162.
Zoeller RT, Dowling AL, Herzig CT, Iannacone EA, Gauger KJ,
Bansal R. 2002. Thyroid hormone, brain development, and
the environment. Environ Health Perspect 110(suppl 3):
355–361.
